However, whether increased MVD and VEGF constituted a prognostic factor for AML treatment response remains unclear (Aref et al., 2005, Padro et al., 2000, Reddy and Moreb, 2000). The gene discussed is VEGFA; the disease is acute myeloid leukemia.